Current treatment landscape for oligometastatic non-small cell lung cancer

查看全文 作　　者：Javier Garde-[1]Noguera;Margarita Martín-[2]Martín;Andres [3]Obeso;Miriam López-[4]Mata;Inigo Royo [5]Crespo;Lira Pelari-[2]Mici;O Juan [6]Vidal;Xabier Mielgo-[7]Rubio;Juan Carlos Trujillo-[8,9]Reyes;Felipe [10,11,12]Couñago

机构地区：[1]Department of Medical Oncology,Hospital Arnau de Vilanova,Valencia 46015,Spain;[2]Department of Radiation Oncology,Hospital Universitario Ramón y Cajal,Madrid 28034,Spain;[3]Department of Thoracic Surgery,Hospital Clínico Universitario de Santiago de Compostela,Vigo 15706,Spain;[4]Department of Radiation Oncology,Hospital Clínico Universitario Lozano Blesa,Zaragoza 50009,Spain;[5]Department of Thoracic Surgery,Hospital Universitari Vall d’Hebron,Barcelona 08035,Spain;[6]Department of Medical Oncology,Hospital Universitario y Politécnico La Fe,Valencia 46026,Spain;[7]Department of Medical Oncology,Hospital Universitario Fundación Alcorcón,Alcorcón 28922,Madrid,Spain;[8]Department of Thoracic Surgery,Hospital de la Santa Creu I Sant Pau,Barcelona 08029,Spain;[9]Department of Surgery,Universitat Autonoma de Barcelona,Barcelona 08029,Spain;[10]Department of Radiation Oncology,Hospital Universitario Quirónsalud Madrid,Madrid 28223,Spain;[11]Department of Radiation Oncology,Hospital La Luz,Madrid 28003,Spain;[12]Medicine Department,School of Biomedical Sciences,Universidad Europea de Madrid,Villaviciosa de Odón 28670,Madrid,Spain

出　　处：《World Journal of Clinical Oncology》索引2022年第13卷第6期,共11页

摘　　要：The management of patients with advanced non-small cell lung carcinoma(NSCLC)has undergone major changes in recent years.On the one hand,improved sensitivity of diagnostic tests,both radiological and endoscopic,has altered the way patients are staged.On the other hand,the arrival of new drugs with antitumoral activity,such as targeted therapies or immunotherapy,has changed the prognosis of patients,improving disease control and prolonging survival.Finally,the development of radiotherapy and surgical and interventional radiology techniques means that radical ablative treatments can be performed on metastases in any location in the body.All of these advances have impacted the treatment of patients with advanced lung cancer,especially in a subgroup of these patients in which all of these treatment modalities converge.This poses a challenge for physicians who must decide upon the best treatment strategy for each patient,without solid evidence for one optimal mode of treatment in this patient population.The aim of this article is to review,from a practical and multidisciplinary perspective,published evidence on the management of oligometastatic NSCLC patients.We evaluate the different alternatives for radical ablative treatments,the role of primary tumor resection or radiation,the impact of systemic treatments,and the therapeutic sequence.In short,the present document aims to provide clinicians with a practical guide for the treatment of oligometastatic patients in routine clinical practice. 关键词：Oligometastatic Non-small cell lung carcinoma Non-small cell lung cancer Oligometastasis

相关文献

参考文献（57）
引证文献（1）
耦合文献（0）

参考文献(57)

引证文献(1)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Current treatment landscape for oligometastatic non-small cell lung cancer

参考文献(57)

引证文献(1)

用户提示